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Background. IgA nephropathy (IgAN) was thought to be benign but recently found it slowly progresses and leads to ESRD
eventually. Theaim of this researchis toinvestigate thevalue of serumIL-18 level, a sensitive biomarker for proximal tubuleinjury,
for assessing the histopathological severity and disease progression in IgAN. Methods. Serum IL-18 levels in 76 IgAN patients and
36 healthy blood donors were measured by ELISA. We evaluated percentage of global and segmental sclerosis (GSS) and extent
of tubulointerstitial damage (TID). The correlations between serum IL-18 levels with clinical, histopathological features and renal
prognosis were evaluated. Results. The patients were 38.85 ± 10.95 years old, presented with 2.61 (1.43∼4.08) g/day proteinuria.
Serum IL-18 levels were signiﬁcantly elevated in IgAN patients. Baseline serum IL-18 levels were signiﬁcantly correlated with
urinary protein excretion (r = 0.494, P = 0.002), Scr (r = 0.61, P<0.001), and eGFR (r =− 0.598, P<0.001). TID scores
showed a borderline signiﬁcance with serum IL-18 levels (r = 0.355, P = 0.05). During follow-up, 26 patients (34.21%) had
a declined renal function. Kaplan-Meier analysis found those patients with elevated IL-18 had a signiﬁcant poor renal outcome
(P = 0.03),andCoxanalysisfurtherconﬁrmedthatserumIL-18levelswereanindependentpredictorofrenalprognosis(β = 1.98,
P = 0.003).
1.Introduction
IgA nephropathy (IgAN), a mesangial proliferative glomeru-
lonephritis (GN), is the most commonly occurring glomeru-
lonephritis worldwide [1]. It was once thought to be relative-
lybenignandtohaveareasonablygoodlong-termprognosis.
However, recent studies indicate that IgAN has the potential
for slowly progressive chronic renal impairment, leading
eventually to ESRD. Approximately 25 to 30% of any pub-
lished cohort will require renal replacement therapy within
20 to 25 years of presentation. From ﬁrst symptoms, 1.5% of
patients with IgAN have been calculated to reach ESRD per
year [2, 3]. Prognostic clinical factors for the future develop-
ment of renal failure include the presence of persistent and
severeproteinuria,elevatedserumcreatinine(Scr)atdiagno-
sis, and the presence of hypertension; meanwhile, histologi-
cally the extent of tubulointerstitial ﬁbrosis correlates better
with reduced renal function than glomerular histology does
[4].
Interleukin-18 (IL-18) is a member of the IL-1 family
of cytokines and was originally described as an interfer-
on gamma (IFN-γ) inducing factor [5]. It is a novel bio-
marker that has been studied in detail in preclinical ische-
mia-reperfusion models and has been proved to play an im-
portant role in renal injury induced by acute ischemia-reper-
fusion in mice [6]. Numerous reports indicate that CKD pa-
tients have elevated serum or urine levels of IL-18 and its
correlation with decreased renal function [7–9]. The aim of
this research was to investigate the relationship of serum IL-
18 levels with histopathological severity and renal prognosis
in IgA nephropathy.
We performed a prospective study using serum IL-18
levels, detailed baseline clinical data, and semiquantitative
analysis of renal biopsies, to assess the correlation between
IL-18 and tubulo-interstitial damage and the value of IL-18
in determining adverse outcomes, mainly disease progres-
sion.2 Mediators of Inﬂammation
2.MaterialsandMethods
2.1. Patients. The study protocol was approved by the Eth-
ics Committee of Shanghai Jiaotong University School of
Medicine(Shanghai,China)(2002HL0133).76patientswere
enrolled (39 females) and followed after they gave fully
informed consent. Inclusion criteria consisted of (1) biopsy-
proven IgA nephropathy, histological grade III or above
according to Lee’s grading system [10] within a 6-month
period, (2) an age of 18 to 65 years, (3) estimated glomeru-
lar ﬁltration rate (eGFR) greater than 30mL/min/1.73m2
according to a modiﬁed Modiﬁcation of Diet in Renal Dis-
ease Study equation [11], and (4) proteinuria ≥1g / 2 4ho n
at least two consecutive laboratory measurements. Exclusion
criteria included (1) rapid progressive IgAN (renal function
deteriorate quickly or historically necrotic capillaritis and
cellular crescents), (2) secondary IgAN such as Henoch-Sch-
¨ onleinpurpura,lupusnephritis,andotherprimaryglomeru-
lonephritis, (3) treatment with steroids or cytotoxic drugs
during the previous 6 months, (4) pregnancy or planning for
pregnancy, and (5) diabetes mellitus, neoplasia, active pep-
tic ulcer disease, viral hepatitis, or other infections. Age-
and sex-matched 36 healthy volunteers were concurrently
enrolled as controls.
After a screening assessment, all patients entered a 4-
week run-in phase in which eGFR and 24-hour proteinuria
were evaluated every 2 weeks. Before enrollment, 28 patients
(36.84%) had been treated with ACE inhibitors (ACEI)
or angiotensin II receptor blockers (ARB). These patients
were required to withdraw the drug at least 4 weeks before
eGFR and proteinuria were evaluated. Other antihyperten-
sive agents were allowed to achieve blood pressure target
(125/75mmHg). At the end of the run-in phase, all eligible
patients were given oral prednisone at an initial dosage of
1mg/kg/d for the ﬁrst 2 months, and gradually tapered by
5mg till 20mg/d, then tapered by 2.5mg to a maintained
dosage at 10mg/d over the next 6 months. Other medication
was given simultaneously including (1) an antiplatelet agent,
regularly aspirin or change to dipyridamole if the patient has
a high risk of bleeding complication, (2) ACEI or ARB, and
(3) other antihypertensive agents that could be used to reach
the blood pressure target. During the study, the dosage of
ACEI or ARB would not change.
2.2. Histopathology of IgAN. Paraﬃn sections were stained
with hematoxylin and eosin, periodic acid-Schiﬀ,t r i c h r o m e ,
and silver for light microscopy. All histopathologic samples
werereviewedandscoredindependentofpreviouspathology
reviews and by 2 independent renal pathologists who were
blinded to previous pathology reviews (in the context of
usual clinical care) and patients’ clinical outcomes. The light
microscopy features of the renal biopsy were examined to
evaluate the glomerular changes, which were classiﬁed into
grades I–V according to the disease severity as described
previously [10]. Global and segmental sclerosis was calcu-
lated as percentages of the total number of glomeruli (GSS).
For tubulo-interstitial lesions, tubular atrophy, interstitial
ﬁbrosis, and interstitial inﬂammatory cell inﬁltration were
scored 0 as absent, 1+ as mild (involving <25% of the
interstitiumandtubules),2+asmoderate(involving25–50%
of the interstitium and tubules), and 3+ as intense (involving
>50% of the interstitium and tubules), then added up to
obtain a ﬁnal score, tubulo-interstitial damage (TID) score,
f r o m0t o9[ 12].
2.3. Clinical Parameters. In the morning, after subjects had
fasted overnight, blood pressure was measured in the right
arm at least twice with a mercury sphygmomanometer after
subjects had rested in the supine position for at ≥5min.
Urineandbloodsampleswerecollectedandanalyzedforbio-
chemistry measurements. Serum concentrations of albumin,
creatinine, lipids, and hemoglobin (Hb) were measured by a
Bayer ADVIA 1650 biochemical instrument. Blood samples
were collected and centrifuged at 1500rpm for 15min. Se-
r u mw e r ec o l l e c t e da n ds t o r e da t−80◦C until analyses.
2.4. Followup and Outcome Deﬁnition. Patients were exam-
ined at baseline, every month for the ﬁrst 6 months, and
then every 3 months. At each visit, body weight, height,
blood pressure, serum biochemistry measurement, and 24-
hour urine protein excretion were measured and recorded.
The primary outcome was time to the composite of the
ﬁrst of (1) doubling of baseline serum creatinine, (2)
ESRD (permanent hemodialysis, peritoneal dialysis, or renal
transplantation), or (3) death from any cause. Treatment
outcome was deﬁned as follows: (1) complete remission
(CR), which means urinary protein excretion <0.3g/24h
on 3 consecutive measurements, serum albumin >35g/L,
and renal function stable. (2) Partial remission (PR), which
means >50% decrease in urinary protein excretion but
>0.3g/24h,serumalbumin>30g/L, and renal function sta-
ble. (3) Not remission (NR), which means <50% decrease in
urinary protein excretion, or deterioration of renal function
but <50% decrease in eGFR or less than doubling of Scr.
2.5. Analytical Procedure of Serum IL-18 Levels. Serum IL-18
levelsweremeasuredusingacommerciallyavailableenzyme-
linked immunosorbent assay kit (Medical and Biologic Lab-
oratories, Nagoya, Japan) that speciﬁcally detects the mature
form of IL-18, as previously described [13]. The coeﬃcient
of variation of inter- and intraassay reproducibility for IL-18
concentration ranges from 5 to 10%, corresponding to that
reported by the kit manufacturer. The measurements were
made in duplicate and in a blinded fashion. Final serum IL-
18 values were expressed in pg/mL.
2.6. Statistical Analysis. Baseline and outcome data were
presented as mean ± SD or median (percentual frequency)
as appropriate and analysed for signiﬁcant diﬀerences using
paired and unpaired t-tests for continuous variables (after
check for normal distribution), the chi-square test, and Fish-
er’s exact test for categorical variables. The Mann-Whitney
U-test and Wilcoxon signed-rank test were used for paired
and unpaired subjects, respectively. Correlation between
serum IL-18 levels and clinical variables were assessed by
Spearman correlation coeﬃcient.Mediators of Inﬂammation 3
Table 1: Demographic, clinical, and histological data in IgAN pa-
tients at baseline.
Parameter Data
Male/female 37/39
Age (year) 38.85 ± 10.95
Smoking history (%) 13 (17.11)
SBP (mmHg) 124.42 ± 19.18
DBP (mmHg) 80.58 ± 12.40
Hemoglobin (g/dL) 124.16 ± 18.74
Proteinuria (g/24h) 2.61 (1.43∼4.08)
sAlb (g/L) 36.12 ± 6.26
Scr (μmol/L) 95.90 (78.00∼118.40)
eGFR (mL/min/1.73m2) 75.83 ± 4.41
sIgA (mmol/L) 3.09 ± 1.15
Hs-CRP (mg/L) 4.56 ± 0.92
Cholesterol (mmol/L) 5.87 ± 1.24
Triglyceride (mmol/L) 2.68 ± 0.61
sIL-18 (pg/mL) 360.26 ± 25.23
Lee’s grading system
Grade III 17 (22.36%)
Grade IV 39 (51.31%)
Grade V 20 (26.32%)
GSS 0.24 (0.09−0.50)
TID 4.00 (2.00−6.00)
Data are mean ± SD or median interquartile range, and comparisons bet-
ween groups were made by the Student’s t-test or χ2 test as appropriate. SBP,
systolic blood pressure; DBP, diastolic blood pressure; SAlb, serum albumin;
Scr, serum creatinine; eGFR, estimated glomerular ﬁltration rate; sIgA,
serum immunoglobulin A; Hs-CRP, high-sensitivity C-reactive protein; sIL-
18, serum interleukin-18; GSS, global and segmental sclerosis; TID, tub-
ulointerstitial damage.
The ability of serum IL-18 to discriminate between mild
andmoderatetoseveretubulo-interstitialdamageduringthe
follow-up period was determined using receiver operating
characteristic (ROC) curves, providing not only sensitivity
and speciﬁcity, but also the area under the curve (AUC) at
diﬀerent cutoﬀ values of serum IL-18. Kaplan-Meier analysis
and logistic regression analysis were used to explore the
value for serum IL-18 levels in predicting renal prognosis.
Adjusted eﬀects of serum IL-18 levels were presented as odds
ratios(OR)with95%conﬁdenceintervals(CI).Two-tailedP
less than 0.05 is considered statistically signiﬁcant. Analyses
were conducted using SPSS 13.0 software program (SPSS,
Incorporated, Chicago, IL, USA).
3. Results
3.1.BaselineCharacteristicsoftheStudyPopulation. Atotalof
76 patients were collected. The patients ranged from 24 to 65
years of age (mean 38.85±10.95 years old), and all presented
with proteinuria with a baseline of 2.61 (1.43−4.08) g/24h
(Table 1). The distribution in Lee’s grading system of 76
patients was grade III, 17 (22.36%); grade IV, 39 (51.31%);
grade V, 20 (26.32%). Compared with healthy controls,
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Figure 1: Serum IL-18 concentration was signiﬁcantly elevated in
patients with IgAN than healthy controls (P<0.01).
baseline serum IL-18 levels were signiﬁcantly elevated in
IgAN patients (360.26 ± 25.23 versus 51.22 ± 8.90pg/mL,
P<0.01, see in Figure 1).
3.2. Serum IL-18 Levels after Treatment and Their Correla-
tion with Responsiveness to Corticosteroid in IgAN Patients.
After corticosteroid therapy, 29 patients showed CR and
22 patients showed PR, totally 51 patients were deemed
responders (R) group (eﬀective rate 67.10%). Those who
showed NR to steroid were deemed non-responders (NR).
The clinical and histological characteristics of the R and NR
patients at the time of enrollment are shown in Table 2.
There were no diﬀerences between the two groups with
respecttoage,gender,bloodpressure,serumalbumin,lipids,
hemoglobin, sIgA, renal function, and GGS, whereas NRs
showed higher TID scores than Rs (P = 0.04). After 12
months therapy, serum IL-18 levels decreased signiﬁcantly
both in the Rs (P<0.01) and NRs (P = 0.01) (Figure 2),
while NRs patients showed much higher baseline IL-18
levels (384.06 ± 15.10 versus 348.35 ± 37.05, P = 0.02).
Multivariate regression analysis model which introduces all
clinical and histological parameters showed that serum IL-
18 levels (β =− 0.003, P = 0.01), serum albumin level
(β = 0.469, P = 0.04), and TID scores (β =− 0.236,
P = 0.018) were signiﬁcantly correlated with corticosteroid
responsiveness (Table 3).
3.3. Correlation between Serum IL-18 Levels with Clinical
and Histological Parameters. Univariate analysis showed that
baselineserumIL-18levelsweresiginiﬁcantlycorrelatedwith
sAlb (r =− 0.395, P = 0.001), urinary protein excretion (r =
0.494, P = 0.002), Scr (r = 0.61, P<0.001), and eGFR (r =
−0.598, P<0.001). With respect to histological parameters,
TID scores showed a borderline signiﬁcance with serum IL-
18 levels (r = 0.355, P = 0.05) whereas GGS did not.4 Mediators of Inﬂammation
Table 2: Clinical and histological data in Rs and NRs patients.
Rs patients
(n = 51)
NRs patients
(n = 25) P value
Age (y) 39.54 ± 11.33 37.58 ± 10.32 0.61
Female, n (%) 23 (45.10%) 12 (50.00%) 0.82
Smokers, n (%) 9 (17.64%) 4 (16.00%) 0.58
SBP (mmHg) 124.4 ± 19.2 121.7 ± 15.6 0.06
DBP (mmHg) 80.6 ± 12.4 77.5 ± 7.5 1.35
Hemoglobin (g/L) 125.17 ± 21.17 134.58 ± 8.98 0.07
Albumin (g/L) 38.03 ± 5.99 36.52 ± 5.61 0.35
Scr (μmol/L) 101.32 ± 36.56 94.73 ± 32.39 0.60
eGFR (mL/min/1.73m2) 73.32 ± 25.27 80.85 ± 29.09 0.45
Urinary protein (g/24h) 2.73 (1.65–3.91) 1.86 (1.28–2.69) 0.13
sIgA (g/L) 3.05 ± 1.07 3.38 ± 0.68 0.33
sIL-18 (pg/mL) 348.35 ± 37.05 384.06 ± 15.10 0.02
GGS (%) 0.22 (0.09–0.43) 0.25 (0.08–0.50) 0.67
TID 3.00 (2.00–4.00) 4.50 (3.00–6.00) 0.04
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Figure 2: In patients respond to corticosteroid therapy (R group),
sIL-18 decreased signiﬁcantly both in responders and nonrespon-
ders (P<0.05) while NRs patients showed much higher baseline
IL-18 levels (P = 0.02).
According to proteinuria levels exceeded 3.5g/24h or
not, we divided our patients into two group. In those who
had higher levels of proteinuria, baseline albumin level was
signiﬁcantly decreased (35.42 ± 8.51 versus 38.21 ± 3.66,
P = 0.02) while serum IL-18 level (402.94 ± 19.86 versus
346.03 ± 15.52, P = 0.02) and percentage of glomerular and
segmental sclerosis (0.35(0.06–0.47) versus 0.24(0.14–0.26),
Table 3: Multivariate regression model to evaluate correlated fac-
tors with responsiveness to steroid therapy.
Parameters βP value
Sex 0.112 0.559
Age (year) 0.023 0.899
Smoke duration −0.362 0.238
SBP (mmHg) 0.279 0.112
DBP (mmHg) 0.022 0.099
Hemoglobin (g/dL) −0.057 0.761
Proteinuria (g/24h) 0.070 0.704
sAlb (g/L) 0.469 0.040
Scr (μmol/L) 0.157 0.384
eGFR (mL/min/1.73m2) −0.195 0.278
sIgA (mmol/L) −0.104 0.570
Hs-CRP (mg/L) −0.078 0.474
Cholesterol (mmol/L) −0.638 0.881
Triglyceride (mmol/L) −0.294 0.729
sIL-18 (pg/mL) −0.003 0.010
Lee’s grading system −0.075 0.676
GSS −0.151 0.398
TID −0.236 0.018
P = 0.05) were signiﬁcantly increased than those with mild
proteinuria (see Table 4).
We further divided our patients into two groups accord-
ing to their TID scores. We found that those with severe
tubulo-interstitial damage had signiﬁcantly higher serum
IL-18 levels than patients with mild to moderate lesion
(367.83 ± 66.83 versus 315.91 ± 65.70, P<0.05). The
AUC-ROCs for the utility of sIL-18 for prediction of
tubulo-interstitial damage were 0.64 (95% CI: 0.45 to 0.83)
(Figure 3). The cutoﬀ value is 323.69pg/mL, its sensitivity is
94.7%, and speciﬁcity is 78.6%, respectively.Mediators of Inﬂammation 5
Table 4: Clinical and histological data between patients with proteinuria above 3.5g/24h or not.
Proteinuria lower than 3.5g/24h
(n = 57)
Proteinuria above 3.5g/24h
(n = 19) P value
Age (y) 38.87 ± 10.76 37.49 ± 9.98 0.88
Female, n (%) 28 (49.12%) 11 (57.89%) 0.67
Smokers, n (%) 10 (17.54%) 3 (15.79%) 0.49
SBP (mmHg) 124.54 ± 18.33 118.8 ± 14.02 0.52
DBP (mmHg) 79.62 ± 10.90 77.24 ± 7.91 0.56
Hemoglobin (g/L) 131.15 ± 19.38 119.78 ± 14.04 0.15
Albumin (g/L) 38.21 ± 3.66 35.42 ± 8.51 0.02
Scr (μmol/L) 100.32 ± 35.42 95.37 ± 35.09 0.99
eGFR (mL/min/1.73m2)7 2 .89 ±25.40 80.64 ± 29.00 0.37
sIgA (g/L) 3.13 ± 0.97 3.26 ± 1.00 0.62
sIL-18 (pg/mL) 346.03 ± 15.52 402.94 ± 19.86 0.02
GGS (%) 0.24 (0.14–0.26) 0.35 (0.06–0.47) 0.05
TID 4.00 (3.00–4.00) 4.50 (2.00–6.00) 0.88
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Figure 3: ROC curve for the utility of serum interleukin 18 levels
for prediction of tubulo-interstitial damage in IgA nephropathy pa-
tients.
3.4. Serum IL-18 Levels Predict Reduction of Renal Function in
Follow-Up Period. Patients enrolled had a median of follow-
up time of 58 (19–120) months. During this period, 4
patients(5.26%) developed thecompositeprimary outcome,
1 patient started hemodialysis, 2 patients started peritoneal
dialysis, and 1 patient did renal transplantation all because
of ESRD. In addition, another 22 patients (28.95%) had
renal function deterioration during followup, whose renal
function estimated by GFR decreased at an average of 0.52 ±
0.16mL/min/1.73m2/month.
Patients were divided into two groups based on whether
the renal function decreased or not. The clinical and histo-
logical characteristics of the diﬀerent outcome patients at the
time of enrolment are shown in Table 5. Patients who had
deteriorated renal function showed higher TID scores (4.00
(3.00−6.00) versus 2.50 (2.00−4.00), P = 0.03), higher IL-
18 levels (before treatment 364.45 ± 40.25 versus 353.67 ±
16.36, P = 0.02; after treatment 132.44 ± 32.40 versus
99.41 ± 24.14, P = 0.04), higher Scr (97.50 (71.20–111.80)
versus 83.10 (71.00–109.70), P = 0.03), lower hemoglobin
level (119.00 ± 21.68 versus 128.79 ± 12.45, P = 0.03), and
lower GFR (71.49 ± 5.11 versus 82.65 ± 7.89, P = 0.04)
than those who had stable renal function at baseline. Besides,
patients who had deteriorated renal function were more
likely to be nonresponsive after corticosteroid therapy.
Univariate analysis found that baseline IL-18 levels
(r = 0.242, P = 0.021), TID scores (r = 0.399, P = 0.032),
Scr (r = 0.466, P = 0.011), and eGFR (r =− 0.455,
P = 0.013) were signiﬁcantly correlated with the rate of loss
of eGFR. The results from the Kaplan-Meier analysis for
overall renal survival are shown in Figures 4 and 5.W ef o u n d
that patients who had higher than median IL-18 levels (P log
rank= 0.03) at baseline and those who had severe tubulo-
interstitial damage (P log rank=0.005) had worse renal
outcome. Baseline serum IL-18 (β = 1.98, P = 0.003), TID
scores (β = 1.96, P = 0.001), and renal function remained
independently associated with the deteriorated renal
outcome in Cox proportional hazard model that adjusted for
age, smoking and history, blood pressure, albumin, lipids,
CRP, and hemoglobin at enrollment (Table 6).
4. Discussion
IgAN is the most common form of glomerulonephritis
worldwide, in which nearly 40% of cases can lead to ESRD in
achronicandprogressiveprocess.Asitspathogenesishasnot
been fully explained, predicting the clinical course has been
diﬃcult, and few treatments have demonstrated a signiﬁcant
reduction in progressive disease. Accurately judging which
individuals will go on to develop progressive disease would
allow physicians to target high-risk patients for aggressive6 Mediators of Inﬂammation
Table 5: Comparison of clinical and histological parameters between IgAN patients with renal function deterioration or not in follow-up.
Parameters Renal function deteriorated
(n = 26)
Renal function stable
(n = 50) P value
Age (year) 39.71 ± 9.59 37.12 ± 11.07 0.38
SBP (mmHg) 130.02 ± 20.18 125.42 ± 18.09 0.27
DBP (mmHg) 85.03 ± 10.40 80.00 ±13.91 0.19
Hemoglobin (g/dL) 119.00 ± 21.68 128.79 ± 12.45 0.03
Proteinuria (g/24h) 2.4 (1.4∼4.0) 2.6 (1.7∼3.1) 0.56
sAlb (g/L) 36.1 ± 6.2 38.9 ± 3.9 0.34
Cholesterol (mmol/L) 5.78 ± 1.36 5.90 ± 1.19 0.89
Triglyceride (mmol/L) 2.49 ± 0.70 2.78 ± 0.58 0.08
Scr (μmol/L) 97.50 (71.20–111.80) 83.10 (71.00–109.70) 0.03
eGFR (mL/min) 71.49 ± 5.11 82.65 ± 7.89 0.04
sIgA (g/L) 3.2 ± 0.7 3.1 ±1.20 . 2 8
Hs-CRP (mg/L) 4.76 ± 1.01 4.34 ±0.98 0.30
sIL-18 at baseline (pg/mL) 364.45 ± 40.25 353.67 ± 16.36 0.02
sIL-18 after treatment (pg/mL) 132.44 ± 32.40 99.41 ± 24.14 0.04
GSS 0.28 (0.09–0.50) 0.25 (0.08–0.43) 0.78
TID 4.00 (3.00–6.00) 2.50 (2.00–4.00) 0.03
Steroid responsiveness (n)1 9 3 2 0 . 0 6
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Figure 4: IgAN patients who had higher than median IL-18 levels
(346.80pg/mL) at baseline had worse renal outcome in follow-up
period (Log rank P = 0.03). In this ﬁgure, green line represents
those patients with higher sIL-18 levels.
treatment or monitoring. However, physicians have been
unable to readily predict individual responses until patients
ﬁnish a course of immunosuppressive treatment nowadays.
As a result, molecular biomarkers may be useful in the dia-
gnosis and prognosis of IgAN in the future.
In this study, we demonstrated that serum IL-18 inde-
pendently predicts the renal function deterioration in IgAN
patients even after adjustment for known clinical predictors.
Sensitivity analyses in this relatively small group of patients
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Figure 5: IgAN patients who had higher TID scores at baseline had
worse renal outcome in follow-up period (Log rank P = 0.005).
In this ﬁgure, green line represents those patients with higher TID
scores.
suggest that IL-18 may be a speciﬁc biomarker to be used
to evaluate the extent of tubulo-interstitial damage, and
even a predictor for disease progression. To the best of our
knowledge, this is the ﬁrst demonstration that IL-18 is an
important predictor of patient renal outcome in an IgAN
population.
IL-18 is primarily a macrophage-derived cytokine; how-
ever, its expression has been reported in a wide range of cells,
including those of bone marrow (BM) origin (macrophages,Mediators of Inﬂammation 7
Table 6: Cox Regression analysis using to evaluate risk factor for renal function deterioration in patients with IgA nephropathy.
Parameter β t P value
TID score 1.96 3.69 0.001
sIL-18 (pg/mL) 1.98 2.77 0.003
Baseline Scr (μmol/L) 0.09 0.19 0.017
eGFR (mL/min/1.73m2) −0.05 0.01 0.023
Proteinuia (g/24h) 2.50 0.33 0.056
Gender 0.56 0.32 0.572
Age (year) −0.19 −3.98 0.312
Smoke history 0.33 0.41 0.746
SBP (mmHg) −0.03 −0.27 0.760
DBP (mmHg) 0.02 0.23 0.821
Hemoglobin (g/dL) 0.22 1.43 0.739
sAlb (g/L) 0.002 0.02 0.734
Cholesterol (mmol/L) 0.07 0.59 0.653
Triglyceride (mmol/L) −0.18 −1.53 0.533
sIgA (g/L) 0.18 1.97 0.812
Hs-CRP (mg/L) 0.13 1.45 0.931
GSS (%) −0.04 −0.36 0.602
dendritic cells, T cells, and B cells) and parenchymal kidney
cells (tubular epithelial cells, podocytes, and mesangial
cells) [14, 15]. Recent studies have suggested that IL-18
may provide substantial prognostic information in diﬀerent
settings, especially in tubular injury. IL-18 was found to po-
tentiate ischemic AKI and to be detectable in the urine of
mice subjected to ischemic kidney injury [6]. Urinary IL-
18 has been studied by Parikh and coworkers in a variety of
clinical settings, including delayed graft function [16], car-
diac surgery, acute respiratory distress syndrome [17], and
cross-sectionally in patients with and without kidney disease
[18]. Urinary IL-18 has also been studied as a biomarker of
contrast nephropathy [19].
It is also described that patients with CKD, especially
those who had a decrease in GFR, have higher serum con-
centrations of IL-18 than the general population [20–22].
Calvani et al. [23] reported that increased glomerular IL-18
expression in a limited number of renal biopsy specimens
from patients with WHO class IV and V lupus nephritis.
Hewins et al. [24] reported that IL-18 is upregulated in
podocytes, interstitial myoﬁbroblasts, inﬁltrating interstitial
macrophages, and distal tubular epithelial cells in the kid-
ney during active ANCA-associated vasculitis. Tubular IL-18
expression is upregulated in murine models of lupus neph-
ritis and renal ischaemia [6, 25].
While in primary IgAN patients, the relationship bet-
ween IL-18 with renal pathology and prognosis has not
been investigated. We supposed that the mechanism of how
elevated IL-18 concentrations predict renal function deterio-
rationmaybeattributedtoitscloserelationshipwithtubulo-
interstitial injury potentiated by inﬂammation. Glomeru-
lotubular crosstalk may participate in the development of
tubulo-interstitial injury in IgAN [26]. Mediators (mainly
TNF-α) released from mesangial cells after IgA deposition
activate tubular epithelial cell (TEC) and lead to subse-
quent inﬂammatory changes in the renal interstitium. The
interaction of IgA with glomerular mesangial cells induces
cell proliferation [27] and the release of cytokines and che-
mokines. Activated mesangial cells produce cytokines and
chemokines, including IL-1, IL-6, TNF-α, monocyte chemo-
tactic protein-1, TGF-β,a n dP D G F[ 28]. We speculate that
these humoral factors/mediators from mesangial cells ﬁrst
activatethepodocytesbeforereachingthetubulointerstitium
either by glomerular ﬁltration or by transportation via the
postglomerular capillaries. Upon reaching the tubular com-
partment, these mediators could stimulate TEC to pro-
duce other proinﬂammatory cytokines such as IL-18 and
chemokines that eventually lead to tubular damage, intersti-
tialmononuclearcellinﬁltration,andﬁbrosisviaamultitude
of mechanisms. IL-18 plays a crucial role in inﬂammation
and in particular modulates the activity of macrophages
[29] by activation of transcription factors including NF-
κB[ 30] and AP-1 [31], inducing transcription of a cascade
of inﬂammatory molecules including inducible nitric oxide
synthase(iNOS)[32],TNF-α[33],chemokines[34],andad-
hesion molecules [35]; therefore, IL-18 may promote im-
mune or nonimmune-mediated tissue damage via am u l t i -
tude of mechanisms.
There were several limitations in the present study. First,
it was a single-center trial with a small study population
carried out over a relatively short period of time. The follow-
up time is relatively short to observe the renal outcome. It
is suggested that an open-labeled, prospective, multicentered
and controlled research is necessary to estimate the value of
IL-18 measurement in IgAN and reduce the bias in ours.
Secondly, it is an observational study which cannot fully
explain why there is a relationship between IL-18 and renal
functiondeteriorationinIgANpatients.Itprovidesacluefor
us to further investigate the mechanism of this phenomenon
and immunosuppressant’s eﬀect. Furthermore, it is notable8 Mediators of Inﬂammation
that an international panel of experts recently produced
guidelines on the reporting of biopsies that demonstrate
IgAN. The Oxford classiﬁcation system suggests that four
features are relevant: (1) mesangial hypercellularity, and(2)
segmental sclerosis, (3) endocapillary hypercellularity, and
(4) tubular atrophy/interstitial ﬁbrosis. Our study supports
the importance of interstitial ﬁbrosis, and glomerular or
segmental sclerosis, although we did not recruit other two
features. The diﬀerences between these results highlight the
need for further large, independent samples to conﬁrm the
relative importance of inﬂammation biomarker and other
histopathologic features in addition to clinical features.
In conclusion, simple histopathologic measures of tub-
ulo-interstitial injury and serum IL-18 may improve the
identiﬁcation of IgAN patients who are at high risk and
have potential for progressive loss of kidney function. These
results require conﬁrmation and validation in an inde-
pendent cohort of patients with biopsy-proven IgAN. We
suggest that higher serum IL-18 may represent an ongoing
inﬂammatoryandﬁbroticprocessinIgAnephropathy,which
indicates for intensive therapy from onset.
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